{"denomUnitsSelected":"Participants","description":"To evaluate the incidence of anti-blinatumomab antibody formation","reportingStatus":"NOT_POSTED","timeFrame":"Assessed at baseline, end of 2 cycles of blinatumomab, end of 4 cycles of blinatumomab, and end of blinatumomab treatment","title":"Incidence of Anti-blinatumomab Antibody Formation","type":"OTHER_PRE_SPECIFIED"}